Volume 144, Issue 5, Pages e1 (May 2013)

Slides:



Advertisements
Similar presentations
Volume 2, Issue 8, Pages (August 2015)
Advertisements

Volume 141, Issue 5, Pages e1 (November 2011)
Volume 10, Issue 2, Pages (August 2006)
Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma  Kuang-Tzu Huang, I-Ying Kuo, Ming-Chao.
Volume 146, Issue 5, Pages (May 2014)
Volume 144, Issue 3, Pages e1 (March 2013)
Volume 146, Issue 7, Pages e3 (June 2014)
Volume 138, Issue 3, Pages (March 2010)
Volume 152, Issue 1, Pages e4 (January 2017)
Volume 138, Issue 4, Pages (April 2010)
Figure S1 C A B D E F G H I MHCC-97H Control NC pCDH kDa
Volume 143, Issue 3, Pages e2 (September 2012)
Volume 133, Issue 2, Pages (August 2007)
Deregulation of SLIT2-Mediated Cdc42 Activity Is Associated with Esophageal Cancer Metastasis and Poor Prognosis  Ruo-Chia Tseng, PhD, Jia-Ming Chang,
Microarray-Based Prediction of Tumor Response to Neoadjuvant Radiochemotherapy of Patients With Locally Advanced Rectal Cancer  Caroline Rimkus, Jan Friederichs,
Level of α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C–Related Hepatocellular Carcinoma  Gia L. Tyson, Zhigang Duan, Jennifer R. Kramer,
Volume 136, Issue 3, Pages e4 (March 2009)
Volume 137, Issue 1, Pages (July 2009)
Volume 151, Issue 2, Pages e12 (August 2016)
Volume 136, Issue 2, Pages e1 (February 2009)
Volume 137, Issue 2, Pages e2 (August 2009)
Volume 141, Issue 5, Pages e1 (November 2011)
Volume 151, Issue 5, Pages (November 2016)
Volume 142, Issue 5, Pages e3 (May 2012)
Volume 2, Issue 4, Pages (April 2008)
Epigenetic Inhibition of Nuclear Receptor Small Heterodimer Partner Is Associated With and Regulates Hepatocellular Carcinoma Growth  Nan He, Kyungtae.
Volume 142, Issue 4, Pages e12 (April 2012)
Volume 133, Issue 5, Pages (November 2007)
Volume 141, Issue 6, Pages (December 2011)
Arjun Pennathur, MD, Liqiang Xi, MD, Virginia R. Litle, MD, William E
Volume 140, Issue 1, Pages e2 (January 2011)
Volume 140, Issue 1, Pages (January 2011)
Volume 10, Issue 2, Pages (August 2006)
Volume 129, Issue 3, Pages (September 2005)
Volume 145, Issue 1, Pages (July 2013)
Volume 146, Issue 7, Pages e3 (June 2014)
Volume 136, Issue 2, Pages (February 2009)
EIF4E Is an Adverse Prognostic Marker of Melanoma Patient Survival by Increasing Melanoma Cell Invasion  Shahram Khosravi, Kevin J. Tam, Gholamreza S.
Volume 146, Issue 5, Pages (May 2014)
Volume 133, Issue 3, Pages (September 2007)
Volume 32, Issue 1, Pages e8 (July 2017)
Volume 143, Issue 6, Pages e5 (December 2012)
Volume 135, Issue 1, Pages (July 2008)
Covering the Cover Gastroenterology
Volume 144, Issue 5, Pages e4 (May 2013)
MicroRNA Signature Predicts Survival and Relapse in Lung Cancer
Volume 152, Issue 1, Pages e4 (January 2017)
Volume 23, Issue 4, Pages (April 2018)
Volume 140, Issue 3, Pages e8 (March 2011)
Volume 144, Issue 2, Pages (February 2013)
Molecular Therapy - Nucleic Acids
Volume 4, Issue 3, Pages (August 2013)
Volume 142, Issue 7, Pages e2 (June 2012)
Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis
Volume 127, Issue 2, Pages (August 2004)
Volume 153, Issue 6, Pages e8 (December 2017)
Volume 22, Issue 3, Pages (January 2018)
Covering the Cover Gastroenterology
Volume 22, Issue 3, Pages (January 2018)
Volume 140, Issue 5, Pages e2 (May 2011)
Volume 133, Issue 2, Pages (August 2007)
Volume 130, Issue 7, Pages (June 2006)
Molecular prognostication of liver cancer: End of the beginning
Long Noncoding RNA BC as a Novel Therapeutic Target for Colorectal Cancer that Suppresses Metastasis by Upregulating TIMP3  Jiaxin Lin, Xin Tan,
Volume 156, Issue 6, Pages (May 2019)
MiR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1  Qi Song, Quanbo Ji, Jingbo Xiao, Fang Li, Lingxiong Wang, Yin.
Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.
Molecular Therapy - Nucleic Acids
Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.
Patient stratification using survival risk prediction and BCLC staging
Presentation transcript:

Volume 144, Issue 5, Pages 1066-1075.e1 (May 2013) Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated With Progression of Hepatocellular Carcinoma and Patient Outcomes  Anuradha Budhu, Stephanie Roessler, Xuelian Zhao, Zhipeng Yu, Marshonna Forgues, Junfang Ji, Edward Karoly, Lun–Xiu Qin, Qing– Hai Ye, Hu–Liang Jia, Jia Fan, Hui–Chuan Sun, Zhao–You Tang, Xin Wei Wang  Gastroenterology  Volume 144, Issue 5, Pages 1066-1075.e1 (May 2013) DOI: 10.1053/j.gastro.2013.01.054 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 Significant differentially expressed metabolites associated with HCC tumors and subtypes. (A) Principal components analysis of all metabolites (n = 469) measured in biospecimens is shown comparing tumor (red) vs nontumor (blue) tissues. Each axes represents 1 of 3 principal components. (B) An S-plot of the normalized metabolite expression (T: tumor vs NT: nontumor) in log2 scale of the 28 tumor, subtype, and survival-related metabolites is shown. Each point represents 1 metabolite in 1 sample, colored by tissue type (HpSC, orange; MH, blue). Metabolites with a Y prefix are currently unknown. Gastroenterology 2013 144, 1066-1075.e1DOI: (10.1053/j.gastro.2013.01.054) Copyright © 2013 AGA Institute Terms and Conditions

Figure 2 Gene surrogates of the 28-metabolite signature are associated with survival and the phosphatidylinositide 3-kinase (PI3K) network. (A) Upper left panel: a plot of the correlation between the 28 metabolites with 169 genes is shown. The orange curve represents the plot of correlation between the 28 metabolites and 169 randomly chosen genes. Upper right panel: a plot of the correlation between the 15 metabolites with 169 genes. The orange curve represents the plot of correlation between the 169 genes and 15 randomly chosen metabolites. For both upper panels, the experimental data are shown in the blue curve. The standard deviation is shown for the randomization analysis. The red dashed line represents the point of largest difference between the experimental and randomized data. Lower panel: hierarchical clustering of 15 metabolites and 169 genes whose expression was altered significantly (P < .05) in tumor tissues of HpSC-HCC. Each row represents an individual metabolite and each column represents an individual gene. Genes were ordered by centered correlation and complete linkage according to their correlation coefficient. Pseudocolors indicate positive (orange) or negative (blue) correlation values or missing values (grey), respectively. The scale represents the correlation values from 1 to -1 in log 2 scale. Metabolites with a Y prefix are currently unknown. (B) Left panel: survival risk prediction of the 217 test cases of the LCI cohort was performed using BRB ArrayTools restricted to the 273 gene set with 2 risk groups (high vs low), 2 principal components, and 1000 permutations of the significance of the log-rank test. A Kaplan–Meier overall survival analysis curve is shown for high- and low-risk survival groups with the log rank P value. Right panel: survival risk prediction of 139 cases of the LEC validation cohort was performed using BRB ArrayTools restricted to the 273 gene set with 2 risk groups (high vs low), 2 principal components, and 1000 permutations of the significance of the log-rank test. A Kaplan–Meier overall survival analysis curve is shown for high- and low-risk survival groups with the log-rank P value. (C) The phosphatidylinositide 3-kinase (PI3K) network is altered in HpSC-HCC. The blue colored genes represent those genes among the 273 gene surrogates that were imported to Ingenuity Pathway Analysis. Gastroenterology 2013 144, 1066-1075.e1DOI: (10.1053/j.gastro.2013.01.054) Copyright © 2013 AGA Institute Terms and Conditions

Figure 3 SCD expression is associated with fatty acid metabolites and with patient outcome. (A) Correlation analysis of SCD and palmitoleate or 15-methylpalmitate is shown. The Spearman r value and P value are presented. (B) A Kaplan–Meier overall survival analysis curve (upper panel) or disease-free analysis curve (lower panel) is shown for high- and low-risk survival groups among the LCI cohort with the log-rank P value based on SCD categorized as high or low according to its median expression among tumor specimens. (C) A Kaplan–Meier overall survival analysis curve (upper panel) or disease-free analysis curve (lower panel) is shown for high- and low-risk survival groups among the LEC cohort with the log-rank P value based on SCD categorized as high or low according to its median expression among tumor specimens. (D) Kaplan–Meier curves show the overall survival of the LCI cohort subgrouped by SCD and AFP. Disc, discordant risk assessments; high SCD expression and low risk predicted by AFP (<300 ng/mL) or vice-versa. (E) Kaplan–Meier curves show the overall survival of BCLC stage A patients among the LCI cohort subgrouped by SCD. Gastroenterology 2013 144, 1066-1075.e1DOI: (10.1053/j.gastro.2013.01.054) Copyright © 2013 AGA Institute Terms and Conditions

Figure 4 Abrogation of SCD reduces cell migration, invasion, colony formation, and tumor formation. (A) Huh7 cells were treated with 100 umol/L SPA or 100 umol/L MUPA for 3 days, incubated for 22 hours in Boyden chambers, and migrating and invading cells were quantified. Left: representative images are shown. Top left panel: a model depicting SPA conversion to MUPA by SCD is shown. (B) Corresponding quantitation of Huh7 migration and invasion data are presented as the mean ± SD of triplicate experiments with P value relative to dimethyl sulfoxide (DMSO). (C) Huh7 cells were treated with metformin (10 mmol/L) for 2 days or 100 umol/L MUPA for 3 days or in combination, incubated for 22 hours in Boyden chambers, followed by quantitation of migration and invasion. Data are presented as the mean ± SD of triplicate experiments with P value (metformin [METf] or MUPA vs DMSO or metformin vs MUPA+metformin). (D) Tumor incidence of Huh7 cells transfected with SCD siRNA or control siRNA after subcutaneous injection into both flanks of immunocompromised mice (n = 5). The percentage of tumor incidence is shown with the log-rank P value (upper panel). Lower panel: the growth curve of tumor xenografts of Huh7 cells transfected with SCD siRNA or control siRNA is shown. Data represent averages ± standard error of the mean. *P < .05 or **P < .001 by a 2-sided Student t test. Gastroenterology 2013 144, 1066-1075.e1DOI: (10.1053/j.gastro.2013.01.054) Copyright © 2013 AGA Institute Terms and Conditions